Tharimmune, Inc. — Director's Dealing 2022

Jan 11, 2022

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Hillstream BioPharma Inc. (HILS)
CIK: 0001861657
Period of Report: 2022-01-11

Reporting Person: Bui Lynne A. (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Options (right to purchase)	$13.20	2023-06-20	Common stock (18939)		Direct

Footnotes

F1: The Registrant issued the Reporting Person the options on June 20, 2018. The options vest as follows: (i) 3,787 options vested on the date of grant and became exercisable on June 20, 2019 and (ii) the balance of the options shall vest and become exercisable in 48 equal monthly installments with the first installment vesting on July 20, 2019.